CAT

903.33

+0.91%↑

298.11

+1.14%↑

GEV.US

1,068

+2.85%↑

RTX

178.75

+0.57%↑

241.21

+3.52%↑

CAT

903.33

+0.91%↑

298.11

+1.14%↑

GEV.US

1,068

+2.85%↑

RTX

178.75

+0.57%↑

241.21

+3.52%↑

CAT

903.33

+0.91%↑

298.11

+1.14%↑

GEV.US

1,068

+2.85%↑

RTX

178.75

+0.57%↑

241.21

+3.52%↑

CAT

903.33

+0.91%↑

298.11

+1.14%↑

GEV.US

1,068

+2.85%↑

RTX

178.75

+0.57%↑

241.21

+3.52%↑

CAT

903.33

+0.91%↑

298.11

+1.14%↑

GEV.US

1,068

+2.85%↑

RTX

178.75

+0.57%↑

241.21

+3.52%↑

Inicio・Lista de Acciones・Ocugen Inc

Ocugen Inc

Abierto

1.46 1.39

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

1.44

Máximo

1.48

Métricas clave
By Trading Economics
Ingresos	-1.5M -19M
Ventas	1.7M 1.5M
BPA	-0.06
Margen de beneficios	-1,250.946
Empleados	116
EBITDA	-987K -17M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+687.07% upside

Dividendos
By Dow Jones
Próximas Ganancias	31 jul 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-125M 501M
Apertura anterior	0.07
Cierre anterior	1.46

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

0.6818 / 0.74 Soporte y Resistencia

Ocugen Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

12 may 2026, 22:50 UTC

Ganancias

Commonwealth Bank of Australia Increases Provisions as 3Q Profit Slips

12 may 2026, 22:49 UTC

Ganancias

Aristocrat Leisure Raises Midyear Dividend, Swells Share Buyback Program

12 may 2026, 22:32 UTC

Ganancias

JBS 1Q Profit Slides Amid Rising Cattle Costs -- Update

12 may 2026, 23:48 UTC

Charlas de Mercado

Nikkei May Decline Amid Uncertainty Over Iran Conflict -- Market Talk

12 may 2026, 22:57 UTC

Charlas de Mercado

Ganancias

JBS Says Consumers Are Looking to Pork for Affordable Protein -- Market Talk

12 may 2026, 22:26 UTC

Ganancias

Aristocrat Leisure to Increase On-Market Share Buyback by A$1 Billion

12 may 2026, 22:25 UTC

Ganancias

Aristocrat Leisure 1H Normalized Pretax Profit A$997.3 Million, Up 9.4% on Year

12 may 2026, 22:25 UTC

Ganancias

Aristocrat Leisure Interim Dividend A$0.50/Security

12 may 2026, 22:24 UTC

Ganancias

Aristocrat Leisure 1H Revenue From Continuing Operations A$3.03 Billion, Down 0.2% on Year

12 may 2026, 22:23 UTC

Ganancias

Aristocrat Leisure 1H Net Profit From Discontinued Operations A$7.0 Million

12 may 2026, 22:23 UTC

Ganancias

Aristocrat Leisure 1H Net Profit From Continuing Operations A$798.5 Million, Up 56%

12 may 2026, 22:19 UTC

Ganancias

CBA: Total Provision Coverage Ratio 1.57%>CBA.AU

12 may 2026, 22:14 UTC

Ganancias

CBA: Business Lending Continued to Grow Above System>CBA.AU

12 may 2026, 22:14 UTC

Ganancias

CBA Had 1.4M Business Transaction Accounts at March 31, Up 7% on Year>CBA.AU

12 may 2026, 22:13 UTC

Ganancias

CBA Household Deposits Grew A$38B in 12 Months Through March>CBA.AU

12 may 2026, 22:12 UTC

Ganancias

CBA Home Loan Balances Grew A$41B in 12 Months Through March>CBA.AU

12 may 2026, 22:12 UTC

Ganancias

CBA 3Q New Home Loan Funding A$45B>CBA.AU

12 may 2026, 22:11 UTC

Ganancias

Correct: JBS NV 1Q EPS 20c, Not 21c >JBS

12 may 2026, 22:11 UTC

Ganancias

CBA: CET1 Level 2 Capital Ratio 11.6%>CBA.AU

12 may 2026, 22:10 UTC

Ganancias

CBA: Customer Deposit Funding Ratio 79%>CBA.AU

12 may 2026, 22:09 UTC

Ganancias

CBA: Underlying Portfolio Credit Quality Remains Sound>CBA.AU

12 may 2026, 22:09 UTC

Ganancias

CBA: Higher Collective Provisions Reflect Geopolitical, Macroeconomic Uncertainty >CBA.AU

12 may 2026, 22:08 UTC

Ganancias

CBA 3Q Loan Impairment Expense A$316M>CBA.AU

12 may 2026, 22:07 UTC

Ganancias

CBA: Costs Up on Higher Cloud Computing Volumes, Software Licenses, AI Investment>CBA.AU

12 may 2026, 22:06 UTC

Ganancias

CBA 3Q Operating Expenses Up 1% Excluding Restructuring, Notable Items>CBA.AU

12 may 2026, 22:06 UTC

Ganancias

CBA: 3Q Underlying Net Interest Margin Was Broadly Stable>CBA.AU

12 may 2026, 22:05 UTC

Ganancias

CBA: Lending, Deposit Volume Growth Offset Impact of Two Fewer Days >CBA.AU

12 may 2026, 22:04 UTC

Ganancias

Commonwealth Bank: Operating Income Flat in March Quarter >CBA.AU

12 may 2026, 22:04 UTC

Ganancias

Commonwealth Bank 3Q Cash Profit Up 4% on Year>CBA.AU

12 may 2026, 22:04 UTC

Ganancias

Commonwealth Bank 3Q Cash Profit Down 1% on 1H Quarterly Average>CBA.AU

Comparación entre iguales

Cambio de precio

Ocugen Inc previsión

Precio Objetivo

By TipRanks

687.07% repunte

Estimación a 12 Meses

Media 11.57 USD 687.07%

Máximo 22 USD

Mínimo 7 USD

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Ocugen Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

7 ratings

Comprar

Mantener

Vender

De acuerdo con 7 analistas que ofrecen calificaciones bursátiles a para Ocugen Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

0.6818 / 0.74Soporte y Resistencia

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There are no events.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.